A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Tirzepatide, a GLP-1 medication already on the market to treat diabetes, is now FDA approved to help those suffering from ...

Tirzepatide works by activating receptors of hormones produced by the intestine to reduce hunger. It can result in weight loss, which may improve sleep apnea. Hypoglossal nerve stimulation is a ...

Additionally, researchers are exploring the possible role of medications in treating sleep apnea. One recent example is tirzepatide (Zepbound), a weight loss injection that was approved by the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

has approved Zepbound ® (tirzepatide) as the first and only prescription treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound is intended to help ...